GRADIENT: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of a Selective Glucocorticoid Receptor Modulator, Relacorilant, in Patients With Autonomous Cortisol Secretion Due to Cortisol-Secreting Adrenal Adenoma(s)/Hyperplasia

Auchus et al. • 2020 • J Endocr Soc. Vol 4, Issue Suppl 1 April-May

Read more

Relacorilant, a Selective Glucocorticoid Receptor Modulator, Induces Clinical Improvements in Patients With Cushing Syndrome: Results From A Prospective, Open-Label Phase 2 Study

Pivonello et al • 2021 • Front. Endocrinol., 14 July 2021

Read more

Efficacy and Safety of the Selective Glucocorticoid Receptor Modulator, Relacorilant (up to 400 mg/day), in Patients With Endogenous Hypercortisolism

Pivonello et al. • 2019 • American Association of Clinical Endocrinologists (AACE) 28th Annual Scientific & Clinical Congress

Read more

Natural History of Adrenal Incidentalomas With and Without Mild Autonomous Cortisol Excess: A Systematic Review and Meta-analysis

Elhassan et al • 2019 • Ann Intern Med.

Read more

Evaluation of evidence of adrenal insufficiency in trials of normocortisolemic patients treated with mifepristone.

Yuen et al. • 2017 • J Endocr Soc. 2017;1(4):237-246.

Read more

U500 Insulin Screening of Diabetic Patients Uncovers a Large Amount of Undiagnosed Hypercortisolism Consistent With Cushing’s Syndrome

Editorial Team • 2017 • Diabetes

Read more

Prevalence of subclinical hypercortisolism in type 2 diabetic patients from the Rio de Janeiro Type 2 Diabetes Cohort Study

Costa et al • 2016 • J Diabetes Complications.

Read more

© 2026 Corcept Therapeutics, Incorporated

Privacy Notice | Terms of Use | Site Map | Your Privacy Choices | LinkedIn | Youtube

Privacy Notice

Terms of Use

Site Map

Your Privacy Choices

LinkedIn

Youtube